We are very excited to be showcasing 6 presentations and 1 poster at Blood 2024. The MRDR team will also located at the Transfusion Research Unit Booth - Number 97. Please pop by if you have any questions about the registry or to say hi!
Dr Betty Gration on behalf of Ken Lim
Biallelic deletion of 1p32 in newly-diagnosed Multiple Myeloma (NDMM) patients associated with inferior outcomes: a report from the MRDR
Board number: H122
Dr Sueh-li Lim
Haematologist, Alfred hospital
Functional High-Risk Multiple Myeloma (FHR-MM) following Lenalidomide-Bortezomib-dexamethasone (RVd) induction or bortezomib-cyclophosphamide-dexamethasone (VCD): An analysis from the Australian & New Zealand Myeloma and Related Diseases Registry (ANZ-MRDR).
8:30 AM - 8:45 AM
Dr Betty Gration
Zamasa Foundation Myeloma Fellow, St Vincent's Hospital Sydney
Treatment of First Relapse of Multiple Myeloma in Australia and New Zealand (ANZ): Treatment Patterns and Outcomes: An ANZ Myeloma and Related Diseases Registry (ANZ MRDR) Analysis.
9:45 AM - 10:00 AM
Dr Elizabeth Moore
Research Fellow, Monash University
More efficient delivery of High-cost standard-of-care Therapies in Relapsed Multiple Myeloma using real-time feedback of Patient-reported outcome measures: the MY-PROMPT-2 trial
8:30 AM - 8:45 AM
Dr Adam Irving
Research Fellow, Monash University
The EpiMAP Myeloma model: A new tool for predicting the impact of changes to the Multiple Myeloma treatment pathway
9:45 AM - 10:00 AM
Dr Sabine Ringkowski
Fellow, Liverpool Hospital
Co-occurrence of Obesity and Diabetes adversely impacts overall survival (OS) in Multiple Myeloma (MM) – an analysis from the Australian and New Zealand Myeloma & Related Disease Registry (ANZ MRDR).
11:30 AM - 11:45 AM
Dr Betty Gration
Zamasa Foundation Myeloma Fellow, St Vincent's Hospital Sydney
Impact of socioeconomic status on utilisation of ASCT and overall survival in multiple myeloma: a report from the Australian and New Zealand (ANZ) Myeloma and Related Diseases Registry (ANZ MRDR)
11:45 AM - 12:00 PM